Fairmount is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies.

Fairmount Funds

Fairmount Partners is an independent investment banking firm focused on serving the needs of middle market and emerging growth companies.

Fairmount Partners

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Randy Scott

Incyte Corporation

Fairmount Funds Management LLC | 948 followers on LinkedIn. Dedicated to investing in promising new therapies pursued by biotechnology
and life science companies | Fairmount is a registered investment adviser with $2.5B+ AUM dedicated to investing in promising new biotechnology companies with a focus on differentiated therapeutics, robust research organizations, and experienced management teams.

Metric
Company Name	Fairmount Funds	Fairmount Partners	Incyte Corporation
Symbol			INCY
MSH ID	COM:FAIRMOUNTFUNDS	COM:FAIRMOUNTPARTNERS	COM:INCYTE
Market	PRIVATE	PRIVATE	STOCKS
Sector	Financial Services & Finance	Financial Services & Finance	Healthcare
Industry	Investment Management	Investment Banking	Biotechnology
Country	US	US	US
Stage
Employee Count			2.52K
Website	fairmountfunds.com	fairmountpartners.com	incyte.com
LinkedIn	fairmount-funds-management-llc		incyte
Founders

Metric
Market Cap			13.66B
Enterprise Value
Monthly Web Traffic	88	647	70.55K
Web Traffic Growth	-0.70	-0.64	-0.09
Valuation
Raised Capital

Metric
Revenue			3.70B
Revenue (LTM)
Revenue (NTM)
Gross Profit			3.44B
EBITDA			904.74M
Operating Income			620.52M
Net Income			597.60M
EPS			2.67
Diluted EPS			2.65
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.93
Operating Profit Margin			0.19
EBITDA Margin			0.24
Net Profit Margin			0.20
Return on Equity			0.15
Return on Assets			0.10
Return on Capital Employed			0.12

FAIR

COM:FAIRMOUNTFUNDS

Fairmount Funds

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			30.70
P/B Ratio			2.65
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			4.09
EV Multiple			64.64

Metric
Days Sales Outstanding			66.47
Days Payables Outstanding			1.82K
Days Inventory Outstanding			137.40
Operating Cycle			207.33
Cash Conversion Cycle			8.90
Asset Turnover			0.83

Metric
Operating Cash Flow			496.49M
Free Cash Flow			449.00M
Cash Flow to Debt			25.17
Operating Cash Flow/Sales			0.22
Free Cash Flow Yield			0.04

Metric
Cash & Equivalents			3.21B
Accounts Receivable			-98.68M
Inventory			62.97M
Goodwill			155.59M
Debt to Capitalization			0.01
Debt to Assets			0.01
Current Ratio			3.80
Quick Ratio			3.55

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.06
R&D to Revenue			0.47
SG&A to Revenue			0.32